Indication intelligence, analysis and sector perception

Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00

October 10, 2018 8:43pm

BOLD closed down -$6.88or -18.73% to $29.83 after Tuesday's +$0.37 to $36.70.

With a 52 week change of +32.63% with ...

... 37.33 M shares outstanding and a float of 29.2 M shares – issue a -8.43% or 1.97 M share short ratio.

Audentes Therapeutics, Inc. (BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases -

.... intends to offer $150 million in a public offering

....and grant the underwriters a 30-day option to purchase up to an additional $22.5 million.

BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager.

A strong point is institutional ownership of 103.95% (?) and a minimal 2.32% owned by insiders. Current cash position of $314.43 M and NO debt enhances the raise.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 8 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.